By Fineline Cube 
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic research collaboration with US-based Atossa Therapeutics Inc. (NASDAQ: ATOS). The partnership aims to utilize Nona’s proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidates for breast cancer. Financial details of the collaboration were not disclosed.
Harbour Mice Platform: A Breakthrough in Antibody Development
Nona Biosciences’ innovative H2L2 Harbour Mice platform leverages transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. This eliminates the need for additional engineering or humanization, streamlining the drug discovery process. The platform is further enhanced by integrating single B cell cloning technology, providing a robust solution for developing therapeutic antibodies and accelerating the timeline for drug development.
Global Recognition and Applications
To date, the Harbour Mice platform has been instrumental in over 250 drug discovery programs across various therapeutic areas. Its ability to generate high-quality, fully human antibodies has earned widespread recognition from global partners, positioning it as a leading technology in the field of therapeutic antibody development.-Fineline Info & Tech